Review



jvm13  (DSMZ)


Bioz Verified Symbol DSMZ is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    DSMZ jvm13
    Jvm13, supplied by DSMZ, used in various techniques. Bioz Stars score: 90/100, based on 26 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/jvm13/JVM-13/10__1158_slash_1078___0432__ccr___17___1193-36-11-30
    Average 90 stars, based on 26 article reviews
    jvm13 - by Bioz Stars, 2026-10
    90/100 stars

    Images

    Related Articles

    other:

    Article Title: Novel BAFF-Receptor Antibody to Natively Folded Recombinant Protein Eliminates Drug-Resistant Human B-cell Malignancies In Vivo
    Article Snippet: H. Qin, L. W. Kwak 1 Novel BAFF-receptor antibody to natively folded recombinant protein eliminates drug resistant human B-cell malignancies in vivo Hong Qin 1†* , Guowei Wei 1† , Ippei Sakamaki 2 , Zhenyuan Dong 1 , Wesley A. Cheng 1 , D. Lynne Smith 1 , Feng Wen 1,3 , Han Sun 1 , Kunhwa Kim 4 , Soungchul Cha 4 , Laura Bover 5 , Sattva S. Neelapu 4 , and Larry W. Kwak 1* 1 Beckman Research Institute City of Hope National Medical Center, Toni Stephenson Lymphoma Center, and Department of Hematology and Hematopoietic Stem Cell Transplantation, Duarte, California, USA; 2 Department of Clinical Infectious diseases, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, Toyama, Japan; 3 Department of Medical Oncology Cancer Center, West China Hospital, Sichuan University, Sichuan, China; 4 Department of Lymphoma and Myeloma, and 5 Department of Immunology The University of Texas MD Anderson Cancer Center, Houston, Texas, USA Running Title: Novel BAFF-R mAb eliminates drug-resistant NHLs in vivo Keywords: Immunotherapy; Antibody; Lymphoma; Drug-resistance; BAFF-R *Corresponding authors Larry W. Kwak, MD, PhD Cancer Center Associate Director, Translational Research & Developmental Therapeutics Director, Toni Stephenson Lymphoma Center Dr. Michael Friedman Endowed Professor Beckman Research Institute of City of Hope 1500 East Duarte Road, Duarte, CA 91010-3000 (626) 218-8913 lkwak@coh.org Hong Qin, MD, PhD Associate Research Professor, Toni Stephenson Lymphoma Center Beckman Research Institute of City of Hope hoqin@coh.org † These authors contributed equally to the project.. Research. on November 27, 2017.. © 2017 American Association for Cancerclincancerres.aacrjournals.org Downloaded from H. Qin, L. W. Kwak 2

    Article Title: The Human CD38 Monoclonal Antibody Daratumumab Shows Antitumor Activity and Hampers Leukemia–Microenvironment Interactions in Chronic Lymphocytic Leukemia
    Article Snippet: The Prolymphocytic Leukemia (PLL) cell lines, MEC1, MEC2 and JVM13 as well as the 128 Burkitt’s lymphoma Daudi cell line were obtained from DSMZ.

    Article Title: The human CD38 monoclonal antibody daratumumab shows anti-tumor activity and hampers leukemia-microenvironment interactions in chronic lymphocytic leukemia
    Article Snippet: The Prolymphocytic Leukemia (PLL) cell lines, MEC1, MEC2 and JVM13 as well as the Burkitt’s lymphoma Daudi cell line were obtained from DSMZ.



    Similar Products

    jvm13  (ATCC)
    93
    ATCC jvm13
    Jvm13, supplied by ATCC, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/jvm13/JVM-13/pm36509891-45-43-44
    Average 93 stars, based on 1 article reviews
    jvm13 - by Bioz Stars, 2026-10
    93/100 stars
    		  Buy from Supplier
    lymphoblastoid leukemic cell line jvm13  (ATCC)
    93
    ATCC lymphoblastoid leukemic cell line jvm13
    (A) Western blot analysis of cyclin D1 in control (shCtrl) and cyclin D1-silenced (shCycD1 #1 and #2) MCL cell lines. Tubulin was used as loading control. Cyclin D1 quantification normalized by tubulin and relative to shCtrl cells is shown. Molecular weights (in kDa) are indicated. (B) RNA-seq experiment in shCtrl and shCycD1 #1 MCL cells. Left, heatmaps showing significantly upregulated (red) and downregulated (green) genes in the three biological replicates. Right, Venn diagrams showing the overlap between differentially expressed genes in Granta-519 (G) and JeKo-1 (J) cells (in bold), which were selected for further analysis. (C) Venn diagrams showing the overlap between either upregulated (red) or downregulated (green) genes in shCycD1 MCL cells and cyclin D1 (CycD1) target genes by ChIP-seq in four MCL cell lines (n = 8,638). Statistical significance was assessed by one-tailed Fisher’s test. (D) Differential expression analysis of the cyclin D1-activated genes identified in MCL cells (n = 448) in CycD1wt or CycD1T286 overexpressing versus control <t>JVM13</t> cells.
    Lymphoblastoid Leukemic Cell Line Jvm13, supplied by ATCC, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/jvm13/JVM-13/pmc08051616-65-23-28
    Average 93 stars, based on 1 article reviews
    lymphoblastoid leukemic cell line jvm13 - by Bioz Stars, 2026-10
    93/100 stars
    		  Buy from Supplier
    jvm13 cells  (ATCC)
    93
    ATCC jvm13 cells
    Binding and cytotoxity of immunotoxins for B-cell tumor lines. The scFvs of Binder 1 and 7 phage were cloned into a toxin vector (PE38) to make single chain immunotoxins. A. Binding to MEC1 cells was confirmed by flow cytometry using and antibody to the toxin. Unstained and anti-toxin controls are shown in red and orange. Binder-1 (left) and binder-7 (right) histograms are shown in light blue. Binder1-scFv-PE38 and Binder7-scFv-PE38 (5, 50, 500 and 5000 ng/ml) were incubated with B. MEC1. C. <t>JVM13</t> or D. Nalm6 cells. The immunotoxin HA22, directed to CD22 was used as a positive control. Viability was determined after 72 hr using the CellTiter-Glo® assay to measure ATP levels.
    Jvm13 Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/jvm13/JVM-13/pmc06383771-77-0-5
    Average 93 stars, based on 1 article reviews
    jvm13 cells - by Bioz Stars, 2026-10
    93/100 stars
    		  Buy from Supplier
    jvm13  (DSMZ)
    90
    DSMZ jvm13
    Binding and cytotoxity of immunotoxins for B-cell tumor lines. The scFvs of Binder 1 and 7 phage were cloned into a toxin vector (PE38) to make single chain immunotoxins. A. Binding to MEC1 cells was confirmed by flow cytometry using and antibody to the toxin. Unstained and anti-toxin controls are shown in red and orange. Binder-1 (left) and binder-7 (right) histograms are shown in light blue. Binder1-scFv-PE38 and Binder7-scFv-PE38 (5, 50, 500 and 5000 ng/ml) were incubated with B. MEC1. C. <t>JVM13</t> or D. Nalm6 cells. The immunotoxin HA22, directed to CD22 was used as a positive control. Viability was determined after 72 hr using the CellTiter-Glo® assay to measure ATP levels.
    Jvm13, supplied by DSMZ, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/jvm13/JVM-13/10__1158_slash_1078___0432__ccr___17___1193-36-11-30
    Average 90 stars, based on 1 article reviews
    jvm13 - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    (A) Western blot analysis of cyclin D1 in control (shCtrl) and cyclin D1-silenced (shCycD1 #1 and #2) MCL cell lines. Tubulin was used as loading control. Cyclin D1 quantification normalized by tubulin and relative to shCtrl cells is shown. Molecular weights (in kDa) are indicated. (B) RNA-seq experiment in shCtrl and shCycD1 #1 MCL cells. Left, heatmaps showing significantly upregulated (red) and downregulated (green) genes in the three biological replicates. Right, Venn diagrams showing the overlap between differentially expressed genes in Granta-519 (G) and JeKo-1 (J) cells (in bold), which were selected for further analysis. (C) Venn diagrams showing the overlap between either upregulated (red) or downregulated (green) genes in shCycD1 MCL cells and cyclin D1 (CycD1) target genes by ChIP-seq in four MCL cell lines (n = 8,638). Statistical significance was assessed by one-tailed Fisher’s test. (D) Differential expression analysis of the cyclin D1-activated genes identified in MCL cells (n = 448) in CycD1wt or CycD1T286 overexpressing versus control JVM13 cells.

    Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

    Article Title: A cyclin D1-dependent transcriptional program predicts clinical outcome in mantle cell lymphoma

    doi: 10.1158/1078-0432.CCR-20-2868

    Figure Lengend Snippet: (A) Western blot analysis of cyclin D1 in control (shCtrl) and cyclin D1-silenced (shCycD1 #1 and #2) MCL cell lines. Tubulin was used as loading control. Cyclin D1 quantification normalized by tubulin and relative to shCtrl cells is shown. Molecular weights (in kDa) are indicated. (B) RNA-seq experiment in shCtrl and shCycD1 #1 MCL cells. Left, heatmaps showing significantly upregulated (red) and downregulated (green) genes in the three biological replicates. Right, Venn diagrams showing the overlap between differentially expressed genes in Granta-519 (G) and JeKo-1 (J) cells (in bold), which were selected for further analysis. (C) Venn diagrams showing the overlap between either upregulated (red) or downregulated (green) genes in shCycD1 MCL cells and cyclin D1 (CycD1) target genes by ChIP-seq in four MCL cell lines (n = 8,638). Statistical significance was assessed by one-tailed Fisher’s test. (D) Differential expression analysis of the cyclin D1-activated genes identified in MCL cells (n = 448) in CycD1wt or CycD1T286 overexpressing versus control JVM13 cells.

    Article Snippet: Cell lines We used two well characterized MCL cell lines ( 13 ), JeKo-1 (ATCC, CRL-3006, RRID:CVCL_1865) and Granta-519 (DSMZ, ACC-342, RRID:CVCL_1818), the lymphoblastoid leukemic cell line JVM13 (ATCC, CRL-3003, RRID:CVCL_1318), and HEK293T (ATCC, CRL-3216, RRID:CVCL_0063).

    Techniques: Western Blot, Control, RNA Sequencing, ChIP-sequencing, One-tailed Test, Quantitative Proteomics

    Binding and cytotoxity of immunotoxins for B-cell tumor lines. The scFvs of Binder 1 and 7 phage were cloned into a toxin vector (PE38) to make single chain immunotoxins. A. Binding to MEC1 cells was confirmed by flow cytometry using and antibody to the toxin. Unstained and anti-toxin controls are shown in red and orange. Binder-1 (left) and binder-7 (right) histograms are shown in light blue. Binder1-scFv-PE38 and Binder7-scFv-PE38 (5, 50, 500 and 5000 ng/ml) were incubated with B. MEC1. C. JVM13 or D. Nalm6 cells. The immunotoxin HA22, directed to CD22 was used as a positive control. Viability was determined after 72 hr using the CellTiter-Glo® assay to measure ATP levels.

    Journal: Antibody therapeutics

    Article Title: Generation of antibody-based therapeutics targeting the Idiotype of B-cell Malignancies.

    doi: 10.1093/abt/tby012

    Figure Lengend Snippet: Binding and cytotoxity of immunotoxins for B-cell tumor lines. The scFvs of Binder 1 and 7 phage were cloned into a toxin vector (PE38) to make single chain immunotoxins. A. Binding to MEC1 cells was confirmed by flow cytometry using and antibody to the toxin. Unstained and anti-toxin controls are shown in red and orange. Binder-1 (left) and binder-7 (right) histograms are shown in light blue. Binder1-scFv-PE38 and Binder7-scFv-PE38 (5, 50, 500 and 5000 ng/ml) were incubated with B. MEC1. C. JVM13 or D. Nalm6 cells. The immunotoxin HA22, directed to CD22 was used as a positive control. Viability was determined after 72 hr using the CellTiter-Glo® assay to measure ATP levels.

    Article Snippet: JVM13 cells were purchased from ATCC.

    Techniques: Binding Assay, Clone Assay, Plasmid Preparation, Flow Cytometry, Incubation, Positive Control, Glo Assay

    Binding of ‘binder 1’ monoclonal antibody to cells. A. Binding to MEC1 cells and B. binding to JVM13 cells. MORAb-009 antibody, also an IgG1, (reactive with surface mesothelin on epithelial tumors) was used as an isotype control. Red=no primary antibody. Blue=isotype control. Green=Binder 1 antibody.

    Journal: Antibody therapeutics

    Article Title: Generation of antibody-based therapeutics targeting the Idiotype of B-cell Malignancies.

    doi: 10.1093/abt/tby012

    Figure Lengend Snippet: Binding of ‘binder 1’ monoclonal antibody to cells. A. Binding to MEC1 cells and B. binding to JVM13 cells. MORAb-009 antibody, also an IgG1, (reactive with surface mesothelin on epithelial tumors) was used as an isotype control. Red=no primary antibody. Blue=isotype control. Green=Binder 1 antibody.

    Article Snippet: JVM13 cells were purchased from ATCC.

    Techniques: Binding Assay, Control